US FDA clears initiation of Phase 3 PULSE-CVD19-001 Study for INOpulse (inhaled nitric oxide therapy) to treat COVID-19

Study will investigate up to 500 patients. Prior studies have shown nitric oxide may provide benefit in SARS-CoV by preventing viral replication, improving arterial oxygenation, reducing need for ventilation support & preventing proliferation of pneumonia lung infiltrates.


Biospace Inc.